DiscoverCME in Minutes: Education in Primary Care
CME in Minutes: Education in Primary Care
Claim Ownership

CME in Minutes: Education in Primary Care

Author: Answers in CME

Subscribed: 11Played: 22
Share
© 2022

Description

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
249 Episodes
Reverse
Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

2025-12-1719:16

Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Jacob Sands, MD / Benjamin Levy, MD, FASCO - What’s Now and What’s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape

Jacob Sands, MD / Benjamin Levy, MD, FASCO - What’s Now and What’s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape

2025-12-1501:03:43

Please visit answersincme.com/860/99120473-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in oncology discuss the latest advances in HER2- and TROP2-directed ADCs for the management of advanced NSCLC, and how these approved and emerging ADCs may impact patients’ treatment algorithms. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting HER2 and TROP2 in the treatment of non-small cell lung cancer (NSCLC; Discuss the clinical impact of approved and emerging HER2- and TROP2-directed antibody-drug conjugates (ADCs) in NSCLC; and Formulate evidence-based strategies for the individualized management of patients with NSCLC using HER2- and TROP2-directed ADCs.
Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs

Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs

2025-12-1201:01:35

Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating B7-H3–directed antibody-drug conjugates (ADCs) in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC); Analyze recent clinical trial findings on B7-H3–directed ADCs in patients with previously treated ES-SCLC; and Formulate evidence-based, multidisciplinary team strategies for incorporating B7-H3–directed ADCs into treatment plans for patients with ES-SCLC, as they become available.
Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management

Nicola Hanania, MD, MS / Surya P. Bhatt, MD, MSPH - Demystifying the Evidence for Biologics in COPD: Strategies for Optimized, Patient-Centered Management

2025-12-1101:04:43

Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD.
Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

Sheilagh M. Maguiness, MD, FAAP / Elizabeth Vainder, MD, FAAP - Escalating Atopic Dermatitis Treatment in Pediatric Patients With Confidence: What Do the Guidelines Tell Us?

2025-12-1018:49

Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.
Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

2025-12-0901:01:30

Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm

Stella Lee, MD / Kathleen Buchheit, MD - Striving for Patient Satisfaction in the Present and Future: Personalizing Treatment in an Evolving Paradigm

2025-12-0831:03

Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care

Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care

2025-12-0501:00:55

Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able to: Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy.
April W. Armstrong, MD, MPH / Linda Stein Gold, MD / Clive M. Liu, MD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease

April W. Armstrong, MD, MPH / Linda Stein Gold, MD / Clive M. Liu, MD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease

2025-12-0301:04:30

Please visit answersincme.com/860/99505211-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.
Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach

2025-12-0217:07

Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.
Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses

2025-12-0101:02:39

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.
Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront

2025-11-2812:26

Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.
Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

Stella Lee, MD / Joseph K. Han, MD, FARS, FAAAAI - Spotlight on Emerging Biologics: Interpreting the Latest Efficacy and Safety Signals

2025-11-2730:23

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

2025-11-2521:11

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches

2025-11-2430:39

Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.
Seenu M. Hariprasad, MD - A Closer Look at Emerging Anti-VEGF Therapies in Retinal Vein Occlusion Management: Practical Guidance for Specialists

Seenu M. Hariprasad, MD - A Closer Look at Emerging Anti-VEGF Therapies in Retinal Vein Occlusion Management: Practical Guidance for Specialists

2025-11-2116:10

Please visit answersincme.com/UPU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in managing patients with retinal vein occlusion (RVO) discusses the use of longer-acting anti-VEGF treatments for treating RVO. Upon completion of this activity, participants should be better able to: Explain the rationale for exploring longer-acting anti-VEGF treatment for patients with retinal vein occlusion (RVO); Differentiate the clinical profiles of available and emerging anti-VEGF treatments for macular edema following RVO, based on the latest evidence; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.
Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

Doreen Addrizzo-Harris, MD - Relieving the Weight of Non-Cystic Fibrosis Bronchiectasis: Updated Strategies for an Evolving Landscape

2025-11-2023:14

Please visit answersincme.com/KUS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary medicine discusses the treatment of patients with non–cystic fibrosis bronchiectasis (NCFB) using dipeptidyl peptidase 1 (DPP1) inhibitors. Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting neutrophilic inflammation in non–cystic fibrosis bronchiectasis (NCFB); Describe the clinical impact of DPP1 inhibitors for treating NCFB, in the context of conventional therapy; Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanomaApply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves; and Apply strategies to enhance outcomes for patients with NCFB as the treatment landscape evolves.
Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

Terry Faleye, MPAS, PA-C / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Beyond Biologics for Psoriasis and PsA: TYK2 Inhibitors and Practical Considerations for Personalizing Care

2025-11-1901:14:45

Please visit answersincme.com/860/100752367-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of psoriatic disease discuss challenges in treatment, emerging TYK2 inhibitor therapies, and evidence-based strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Recognize how nurse practitioners and physician associates can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans.
Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

Stella Lee, MD / Kathleen Buchheit, MD - Advances in CRSwNP: Rethinking Biologics and Inflammation at the Source

2025-11-1828:25

Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents.
Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes

2025-11-1817:08

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.
loading
Comments 
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States